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Objective:Despite the efficacy of collagen in femoral artery pseudoaneurysm treatment, as reported in one patient study, its use
has not yet gained wide acceptance in clinical practice. In this particular study, the collagen was not described in detail. To
further investigate the potential of collagen preparations, we prepared and characterized highly purified injectable fibrillar type
I collagen and evaluated its use for femoral artery pseudoaneurysm (PSA) treatment in vivo using a pig model.
Methods: Purified fibrillar type I collagen was characterized using electron microscopy. The effect of three different
sterilization procedures, ie, hydrogen peroxide gas plasma (H2O2), ethylene oxide gas (EtO), and gamma irradiation, was
studied on both SDS-PAGE and platelet aggregation. Different collagen injectables were prepared (3%, 4%, and 5%) and
tested using an injection force test applying a 21-gauge needle. To evaluate the network characteristics of the injectable
collagen, the collagen was suspended in phosphate buffered saline (PBS) at 37°C and studied both macroscopically and
electron microscopically. To determine whether the collagen induced hemostasis in vivo, a pig PSA model was used
applying a 4% EtO sterilized collagen injectable, and evaluation by angiography and routine histology.
Results: Electron microscopy of the purified type I collagen revealed intact fibrils with a distinct striated pattern and a
length <300 m. Both SDS-PAGE and platelet aggregation analysis of the sterilized collagen indicated no major
differences between EtO and H2O2 sterilization, although gamma-irradiated collagen showed degradation products.
Both 3% and 4% (w/v) collagen suspensions were acceptable with respect to the force used (<50 N). The 4% suspension
was selected as the preferred injectable collagen, which formed a dense network under physiologic conditions. Testing the
collagen in vivo (n 5), the angiograms revealed that the PSA partly or completely coagulated. Histology confirmed the
network formation, which was surrounded by thrombus.
Conclusions: Collagen injectables were prepared and EtO sterilized without major loss of structural integrity and platelet
activity. In vivo, the injectable collagen formed a dense network and triggered (partial) local hemostasis. Although
optimization is needed, an injectable collagenmay be used as a therapeutic agent for femoral PSA treatment. (J Vasc Surg
2010;52:1330-8.)
Clinical Relevance: This study explores the use of collagen for femoral artery pseudoaneurysm (PSA) treatment. The
efficacy of collagen has been reported in one patient study, but it has not gained acceptance for PSA treatment. The
current study combines the characterization of a collagen preparation with its evaluation using a porcine model for PSA.
First, injectable collagen was prepared and the optimal sterilization technique selected, addressing structural character-
istics and platelet activity. Next, the collagen preparation was evaluation for PSA treatment using a porcine model. The
results of this study may support the design and application of new collagen injectables.From the aDepartment of Biochemistry 280, NCMLS, Radboud University
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1330A femoral artery pseudoaneurysm (PSA) is a complica-
tion that may occur after arterial puncture for invasive
cardiovascular procedures. When an arterial puncture site
fails to seal, arterial blood jets into the surrounding tissues
and forms a pulsatile hematoma. In 0.2% to 7.7% of the
femoral arterial interventions, a femoral PSA is formed that
needs treatment.1-4 When a PSA is left untreated, rupture
or distal embolization may occur. PSA enlargement may
give rise to pain, neuropathy, and venous obstruction.
Since spontaneous repair of larger pseudoaneurysms is un-
likely, a reliable and easy method to induce local hemostatic
clotting is desirable. Various techniques (eg, ultrasound-
guided compression repair, percutaneous thrombin injec-
tion, balloon occlusion, stent graft placement) have been
used to stop arterial bleeding to replace standard compres-
sion treatment and shorten hospital stay.5-10 Thrombin
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pecially complex pseudoaneurysms), it is not efficient and
even contraindicated. Contraindications for the use of
thrombin injection are the wide and/or short necked
pseudoaneurysms.11 Several cases have reported thrombin
failure in these complex pseudoaneurysms.12-14 Particularly
in these cases, injectable collagen may be an attractive
agent, since collagen is highly viscous and collagen fibrils
aggregate and deposit at the site of injection. In one study,
the potentials of injectable collagen for PSA treatment in
patients was described, and a very high success rate was
reported.15 To follow up on this study, we prepared a
well-characterized injectable collagen preparation and eval-
uated its use in a porcine model for PSA treatment.
Collagen is a well-known structural extracellular matrix
protein. It has found ample usage as a biologic material for
medical applications indicating its versatility as a biomate-
rial, including its use as a drug delivery device16,17 and as a
matrix for the repair and regeneration of tissues.18-20 In
addition, it is used as an adjunct for hemostasis.21-23
Collagen-based plugs are widely used to manage the arte-
rial puncture site and to prevent the extravasation of arterial
blood.24,25 When collagen comes in contact with blood,
platelets become activated and their shape changes, re-
sulting in the release of hemostasis-stimulating com-
pounds, platelet adhesion, and aggregation to the vessel
wall. This process is also known as primary hemosta-
sis.26,27 Collagen is biocompatible and biodegradable
and allows remodelling in the host after implantation. In
addition, collagen can be fabricated in various physical
forms like gels, films, and sponges. These characteristics,
in combination with its hemostatic activity, make colla-
gen a good alternative for current treatments of femoral
PSA.
In 2002, Hamraoui et al treated PSA patients with
bovine fibrillar type I collagen aiming for a less invasive
percutaneous treatment.15 According to this study, the use
of collagen is a safe and effective strategy. To further
elaborate on the use of collagen for PSA treatment, we
prepared well-characterized collagen fibrils, selected the
optimal sterilization procedure, and evaluated its use for
the treatment of PSA using a recently described porcine
model.
METHODS
Materials. Unless otherwise stated, chemicals were
obtained from Merck (Darmstadt, Germany) and were of
the highest purity available.
Preparation of injectable fibrillar type I collagen.
Fibrillar type I collagen was isolated from 6-month-old
bovine Achilles tendon (deep flexor) applying extraction
procedures using neutral salt solutions, chaotropic agents,
dilute acid, and acetone.28 After purification, type I colla-
gen was lyophilized using a Sublimator 500II lyophilizer
(Zirbus Technology, Bad Grund, Germany) and sterilized
using either ethylene oxide gas (EtO; 24 hours at 35-45°C
and at 50%-80% relative humidity; Sterigenics, Zoetermeer,
TheNetherlands), hydrogen peroxide gas plasma (H2O2; 6mg/L at 35°C for 30 minutes), or gamma irradiation
(Gamma; 20 kGy from a 60Co source in an X-ray pallet
irradiator (JS 9000; Isotron BV, ’s-Hertogenbosch, The
Netherlands)). Type I collagen suspensions were prepared
by incubation of 3.0, 4.0, or 5.0 g type I collagen in 100
mLMilliQwater for 16 hours at 4°C. The suspensions were
homogenized (20 times on ice) using a Potter-Elvehjem
homogenizer with an intervening space of 0.35 mm.
Characterization of injectable fibrillar type I collagen.
Scanning electron microscopy (SEM) was used to analyze
the morphology and length of the purified collagen fibrils,
and transmission electron microscopy (TEM) was applied
to study the ultrastructure of the collagen fibrils. Collagen
samples were frozen at 20°C and subsequently lyophi-
lized. Poly-D-lysine coated glass inserts were incubated
with collagen suspensions (0.5 mg collagen/mL 0.25 M
acetic acid), for 16 hours at 4°C, washed three times with
MilliQ water, and air dried. Inserts were mounted on stubs
and sputtered with an ultra thin layer of gold in a Polaron
E5100 coating system (Quorum Technologies, Neuhaven,
United Kingdom). The morphology of the collagen fibrils
was studied in a Philips XL30 ESEM FEG apparatus (Phil-
ips, Eindhoven, The Netherlands) at an accelerating volt-
age of 10 kV, and length studied with a JEOL JSM-6310
SEM (JEOL Ltd, Tokyo, Japan) at 15 kV; 100 fibrils were
randomly measured at 500 magnification in 16 fields.
The ultrastructure of the collagen fibrils was analyzed in the
diluted collagen samples using TEM. The samples were incu-
bated on formvar-coated grids for 1 hour at 21°C, washed
with 0.1 M phosphate buffer (pH 7.4), washed two times
with MilliQ water, stained with 0.1% (w/v) uranyl acetate,
and examined in a JEOL 1010 TEM (Tokyo, Japan).
The purity and intactness of the type I collagen before
and after sterilization was analyzed using sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE).
Samples were incubated at 95°C for 10 minutes under
reducing conditions (5% (v/v) 2-mercaptoethanol) and
analyzed on an 8% (w/v) gel.29 Only potential impurities
and degradation products will penetrate the gel since col-
lagen fibrils are insoluble in sample buffer. Gels were
stained with 0.1% (w/v) Coomassie Brilliant Blue R-250
solution (ICN Pharmaceuticals, Calif), containing 50%
(v/v) methanol and 10% (v/v) acetic acid.
To evaluate the network characteristics of the type I
collagen under physiologic conditions, the injectable colla-
gen suspension (4% (w/v) in MilliQ), was injected in
phosphate buffered saline (PBS, pH 7.4) at 37°C. In addi-
tion, to study this on the electron microscopic level, a
collagen suspension (0.5% (w/v) in MilliQ water) was 1:1
diluted with PBS at 37°C. Collagen suspension (0.5%
(w/v) inMilliQwater) 1:1 diluted inMilliQwater was used
as a control. The collagen was analyzed using the JEOL
JSM-6310 SEM apparatus as previously described.
Injection characteristics of type I collagen suspension.
To determine the force that is needed to inject type I
fibrillar collagen suspension, an injection force test was
performed.30 Different collagen suspensions (3%, 4%, and
5% [w/v] in MilliQ water) were extruded from a 1 mL
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performed at a crosshead speed of 1.8 mm/s. The force was
recorded by an MTS 810 testing machine combined with
an MTS 458.20 microconsole (MTS Systems Corporation,
Eden Prairie, Minn).
Platelet aggregation. Platelet aggregation and thro-
mbus formation is dependent on the structure of the colla-
gen preparation.31 To assess the effect of sterilization of the
injectable collagen on the platelet activity, platelet aggre-
gation was measured. The test was performed in a four-
channel whole-blood aggregometer model 590 (Chrono-
Log Corp, Havertown, Penn) measuring the impedance
(%), that is increased proportional with the amount of
platelet aggregation.31,32 Briefly, whole blood was col-
lected by vena puncture from a healthy volunteer and
collected in 3.2% (w/v) sodium citrate tubes (mean platelet
count: 274·103  30·103/L). Whole blood was diluted
with PBS in a 1:1 ratio and incubated for 15 minutes at
37°C. Next, 10 L collagen suspension (0.05 mg/mL
MilliQ water) was added to 1.0 mL diluted blood. All
measurements were completed within 2 hours from the
blood draw. The platelet aggregation of nonsterilized col-
lagen was set on 1 arbitrary unit (AU). Single way ANOVA
was used for statistical analyzes and P .05 was considered
Fig 1. Morphology and length of purified type I collag
purified type I collagen fibrils (A) and (B), respectively
preparation (C). Results are mean  SD of three separat
(B) is 0.2 m.statistically significant.Evaluation of injectable collagen in a porcine model
for femoral artery pseudoaneurysm. To study the effec-
tiveness of injectable collagen fibrils for treatment of pseu-
doaneurysm a pig model was used as described.33 This
study was approved by the ethics committee (EC) of the
Radboud University, Nijmegen, The Netherlands, and
conducted under the supervision of veterinarians according
to the National Institutes of Health (NIH) guidelines for
the care and use of laboratory animals (NIH publication
85-23 Rev. 1985). The pigs were housed at the Central
Animal Facility, Nijmegen, The Netherlands. The animals
were fed a normal laboratory diet and water ad libitum.
Briefly, the femoral artery and femoral vein in the groin of
an adult pig were exposed and temporarily clamped. A
longitudinal arterio-venous anastomosis (side to side) with
a 4 mm opening was prepared and about a 2 cm segment of
the femoral vein was used as PSA model after closing the
femoral vein both proximally and distally using nonabsorb-
able ligatures. The muscle layer and skin were closed.
Amoxicillin (20 mg/kg/day) was injected intramuscularly
for 4 days to protect the animal from bacterial infections.
The animals received 2 mg/kg carbasalate calcium (Meda
Pharma BV, Amstelveen, The Netherlands) and 0.75
rils. Scanning and transmission electron micrograph of
the distribution of fibril length (m) in the collagen
eriments. Bar in (A) is 1 m and inset is 0.2 m. Bar inen fib
, and
e expmg/kg clopidogrel (Bristol-Myers Squibb/Sanofi Pharma-
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days, as interim anticoagulant and pain medication.
Four days after construction of the PSA model, the
animals were anesthetised and the operation site was re-
opened to evaluate if the PSA model was pulsatile and to
directly inject the collagen preparation. Using a 21-gauge
needle, 4% (w/v in MilliQ water) EtO sterilized 4% (w/v)
collagen suspension (100-200 L) was injected in the PSA
compartment of six individual pigs, and the blood coagu-
lation, host response, and network properties of the colla-
gen evaluated. Intraoperative femoral artery angiography
was performed to document the blood flow in the PSA
model before and after collagen injection. A contrast agent
(Xenetix 300; Codali Guerbet, Brussels, Belgium) was used
as an intravascular flow tracer. The angiogram was per-
formed by accessing the contralateral site with a 6F sheath
(Cordis, Miami, Fla). A 5F angiographic catheter (Boston
Scientific, Natick, Mass) was introduced and positioned
across the aortic bifurcation in the ipsilateral proximal
common femoral artery over a guidewire. All angiograms
were performed with a Philips BV-25 C-arm image inten-
sifier (Philips, Eindhoven, The Netherlands). After removal
of the catheters, the wound was closed. Six days after the
initial evaluation, a second angiogram was performed, and
the animal was subsequently sacrificed by an overdose of
intravenous barbiturate. The area of the pseudoaneurysm
and the surrounding tissue was explanted and immediately
fixed in 4% (v/v) formaldehyde in 10mMphosphate buffer
(pH 7.2) for 24 hours at 4°C and embedded in paraffin.
Consecutive 5 m sections were mounted onto glass slides,
dewaxed in xylol, and rehydrated through a graded series of
ethanol. Hematoxylin and eosin (H&E) staining was em-
ployed for histological evaluation.
RESULTS
Characterization of type I collagen. Scanning elec-
tron microscopy (SEM) and transmission electron micros-
copy (TEM) were used to analyze the morphology and
ultrastructure of the purified type I collagen fibrils. Both
SEM and TEM showed intact fibrils with distinct striated
pattern, and no impurities could be detected (Fig 1, A and
B). The striated pattern reflects the three-dimensional or-
ganization of (triple helical) collagen molecules within a
collagen fibril. The measured length of collagen fibrils (Fig
1, C) indicated that fibril length was400 m, 75% of the
fibrils being 150 m.
SDS-PAGE was used to biochemically characterize the
collagen before and after sterilization (Fig 2). For native
type I collagen, SDS-PAGE showed 1 and 2 bands that
are typical for type I collagen (Fig 2; lane 1). No major
differences were found before and after EtO sterilization or
H2O2 sterilization (Fig 2; lanes 2 and 3). After gamma
sterilization, however, a smear appeared on the gel, indicat-
ing collagen degradation products (Fig 2; lane 4).
Platelet aggregation. A whole-blood platelet aggre-
gation test was used to analyze the effect of sterilization on
platelet aggregation (in arbitrary units). The platelet aggre-
gation of the native nonsterilized collagen was set to 1arbitrary unit. The platelet aggregation of EtO, H2O2, and
gamma was 1.05  0.14, 0.63  0.14, and 0.73  0.09,
respectively (Fig 3). Although EtO sterilized collagen was
Fig 2. Effect of sterilization procedure on the integrity of colla-
gen. SDS-PAGE under reducing conditions of fibrillar type I
collagen before (lane 1) and after (lanes 2-4) sterilization, viz.:
ethylene oxide gas sterilization (lane 2), hydrogen peroxide (H2O2)
gas sterilization (lane 3), or gamma irradiation (lane 4). The low
molecular weight marker is visualized in lane 5. This is a combined
image taken from two separate gels (lanes 1, 2, and 4 are from one gel).
Note that especially after gamma sterilization, collagen degradation
products are observed.
Fig 3. Effect of sterilization on platelet aggregation of fibrillar
collagen. Collagen before sterilization was set on 1 arbitrary unit
(AU). Results are mean  SD for three separate experiments.
Sterilized collagen showed no statistical significant differences in
comparison to nonsterilized collagen (P  .05). EtO, Ethylene
oxide gas sterilization; Gamma, gamma irradiation; H2O2, hydro-
gen peroxide sterilization.most comparable to the nonsterilized collagen, other ster-
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sterilized collagen was used for in vivo studies.
Characterization of type I collagen injectability. An
injection force test was performed to analyze the effect of
different concentrations of type I collagen on injectability
(Fig 4, A). The force was measured while extruding a 3%,
4%, or 5% (w/v) suspension from a 1 mL syringe through a
2F (21 gauge, 0.7 mm) needle. The suspensions required a
force of 18 N, 19 N, and 117 N, respectively (Fig 4, B).
According to ISO regulations, both 3% and 4% (w/v)
collagen suspensions are acceptable and can be used for
manual injection (50 N according to ISO 7886-1:1997;
Sterile hypodermic syringes for single use - Part 1: Syringes
for manual use). The 4% (w/v) collagen suspension was
selected as the preferred injectable collagen suspension.
To analyze the network properties of the injectable type
I collagen under physiologic conditions, the 4% (w/v)
collagen in MilliQ water (Fig 5, A) was applied to pre-
heated (37°C) phosphate buffered saline (pH 7.4). Macro-
scopic evaluation indicated that the collagen formed a dense
network immediately after extrusion in PBS (Fig 5, B).
SEM analyzes indicated a decrease in spacing between
the collagen fibrils, which is in line with aggregation of
fibrils into a network (Fig 5).
Evaluation of injectable collagen in a porcine model
for femoral artery pseudoaneurysm. No complications
due to the surgery were observed. In one of six cases, the
femoral PSA model clotted directly after the operation and
this model was excluded from the experiment. No bleeding
complications occurred as a result of surgery.
Four days after surgery, the PSA was evaluated with
angiography before and after collagen injection. When the
PSA model was open (Fig 6, A), 100 to 200 L 4% (w/v)
type I collagen in MilliQ water was locally injected. In four
of the five cases, the PSA model partly or completely
Fig 4. Evaluation of injectability. Macroscopic image o
in a 1 mL syringe (A). Graph of displacement test (1.8 m
type I collagen suspension in a 1 mL syringe with a 2F (
and on the X-axis displacement is shown in mm. Results a
and white dashed line indicate the 1 mL syringe in the di
the pressure plate.coagulated within approximately 5 minutes after type Icollagen injection, which was confirmed with angiography
(Fig 6, B). In one case, both femoral artery and PSA
coagulated. In this case, both femoral arteries were found
open 6 days after injection leaving the PSA nicely closed
(data not shown). After cross sectioning the injected PSA,
both the collagen and the thrombus were macroscopically
visible and could be localized (Fig 7).
Histologic evaluation. Six days after injection, a mi-
nor infiltration of inflammatory cells was observed (Fig 8,
A). Specimens demonstrated a prominent thrombus and
partial leukocyte infiltration toward the center of the
thrombus (Fig 8, B). The PSA wall was clearly visible and
the injected collagen was observed in a network that ap-
peared to be interconnected with the thrombus.
DISCUSSION
Collagen is well known for its hemostatic activity and
has been widely used as a biodegradable plug to prevent
hemorrhagic complications after arterial puncture, ie, cath-
eterization or coronary angioplasty.34,35 To our knowl-
edge, only one study describes the use of collagen treat-
ment after femoral PSA occurrence.15 Despite the reported
efficacy of this study (97%), its use has not currently gained
wide acceptance.21 However, the promising results of this
study warrant further investigations to the use of collagen
for PSA treatment.
Compared with thrombin there may be several addi-
tional values for use of collagen for (complex) PSA treat-
ment. The first advantage may lay in its physico-chemical
properties. With fibrillar type I collagen as an injectable, the
consistency of the material is important. Collagen swells at
low pH,36 making it possible to prepare a suspension or
paste which can be injected. When the pH of the collagen
suspension was increased to a physiological range (pH 7.4),
the collagen fibrils formed a dense network. After applying
displacement test set up with type I collagen suspension
with maximal distance 44 mm) of 3%, 4%, and 5% (w/v)
m) needle (B). On the Y-axis, force is given in Newton,
an SD of three separate experiments. The white arrow
ment set up. The black arrow and dashed circle indicatef the
m/s
0.7 m
re me
splacethe injectable collagen in the PSA model, fibrils aggregated
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trated this collagen network, which is commonly found
after applying collagenous biomaterials in vivo.37 The con-
sistency and the ability to form a network may be an
advantage to reduce the risk of arterial influx of collagen
fibrils. In addition, complex pseudoaneurysms have been
described as contraindications for thrombin treatment.11
Several cases reported thrombin failure in these complex
pseudoaneurysms.12-14 The soluble thrombin may quickly
diffuse through the wide neck of the pseudoaneurysm
toward the lumen of the artery. In most cases, these com-
plex pseudoaneurysms need to be revised surgically. Espe-
cially in such cases, injectable collagen can be an attractive
agent, since collagen is highly viscous and collagen fibrils
aggregate and deposit at the site of injection, as shown in
this study. The pseudoaneurysm model used in this study
involves the preparation of an arteriovenous shunt between
the femoral artery and femoral vein, where 2 cm of the
Fig 5. Aggregation of injectable collagen under phys
collagen suspension in MilliQ water (A) and the network
in pre-heated (37°C) phosphate buffered saline (PBS, pH
a 0.5% (w/v) collagen suspension in MilliQ water or in P
fibril network (D), respectively. Under physiologic condi
Arrows in (A) and (B) indicate the aggregated type I coll
collagen fibrils. Bar is 10 m in (C) and (D).vein is segmented by proximal and distal closure usingligatures. This model presents a complex pseudoaneurysm
(with a relative wide opening [4 mm]33) and makes the
experimental model highly challenging with respect to
pseudoaneurysm treatment.
A second issue may be the difference in immunogenic-
ity between thrombin and collagen. There are several re-
ported cases of immune complex reactions to bovine
thrombin resulting in antibody formation. Although less
for recombinant human thrombin,38 the antibodies may
cross-react with the coagulation cascade, resulting in factor
inhibition and clinical coagulopathy. Forty percent to 66%
of patients who underwent cardiac surgery and 20% of
patients who underwent neurosurgery developed bovine
thrombin-associated factor V antibodies.39 This complica-
tion may be overcome by the use of collagen, since fibrillar
bovine collagen is almost nonimmunogenic.
Other advantages may relate to technical issues. The
injectability of collagen is critical for its clinical performance
c conditions. Macroscopic images of 4% (w/v) type I
was formed directly after injection of the type I collagen
B). Scanning electron microscopic images after applying
sulting in an open fibril network (C) and an aggregated
(PBS, 37°C), the collagen fibrils formed a dense network.
suspension. Arrowheads for (D) indicate the aggregatediologi
that
7.4) (
BS, re
tions
agenand for patient comfort, eg, in case of the use of collagen as
ate th
k. Ba
JOURNAL OF VASCULAR SURGERY
November 20101336 Geutjes et ala dermal filler.40 Especially for percutaneous PSA treat-
ment, it is important that the agent can be injected through
a needle with a limited diameter. In the clinical study of
Hamraoui et al, a 1% (w/v) collagen suspension was in-
Fig 6. Angiograms of the porcine femoral pseudoaneu
(A) and at day 10 (6 days after collagen injection) (B
arrowheads). In (A), the PSAwas open. In (B), it was clos
of arterial blood flow in the femoral artery (FA).
Fig 7. Macroscopic image of cross-sectioned pseudoan
no. 1, day 10). FA, Femoral artery; PSA, pseudoaneurysm
(4% [w/v] in MilliQ water). The white dashed lines indic
Fig 8. Microscopic images of coagulated pseudoaneur
injection. Hematoxylin-eosin stained sections showed a c
cells (black arrows) (A) and (B). The wall of the PSA is in
collagen network (white arrows) (B). c, Collagen networjected through a relatively large 9F (Ø 3mm) needle, whichmay come with discomfort for the patient. In our suspen-
sion, the collagen content was higher (4% [w/v]) and could
be injected through a 2F (Ø 0.7 mm) needle, which is
comparable with the procedure using thrombin injections
(PSA) (animal no. 6) at day 4 before collagen injection
weezers were positioned on the PSA segment (white
er collagen injection.White arrows indicate the direction
m (PSA) model, 6 days after collagen injection (animal
el with thrombus; c, injected type I collagen suspension
e boundary of the PSA wall. Bar indicates 5 mm.
PSA) model (luminal site) 6 days after type I collagen
PSA filled with type I collagen (c) and coagulated blood
ed by dashed line (A). Leukocytes were found within the
r indicates 500 m in (A) and 50 m in (B).rysm
). T
ed afteurys
modysm (
lotted
dicat(Ø 0.6 mm).21 In addition, one well-known technical
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needle tip resulting in injection problems.41With injectable
collagen we did not observe this problem. The high con-
sistency of the collagen may prevent the entrance of blood
into the needle and subsequent clot formation.
Proper sterilization is an important issue when using
injectable collagen for medical applications. The injectable
collagen must be supplied as a sterile product, but the
efficacy of the collagen must not be compromised by the
sterilization technique. It has been described that tech-
niques like gamma irradiation affect the structural proper-
ties of the collagen fibrils.42,43 This may adversely affect the
platelet aggregation and thrombus formation. For this
reason, we tested different sterilization techniques and
evaluated both biochemical and primary hemostatic char-
acteristics. Both EtO and H2O2 sterilized collagen did not
compromise the integrity of the collagen. We selected EtO
for its tendency to have less influence on collagen-induced
platelet aggregation. In vivo, the injectable collagen sus-
pension did induce local hemostasis within an approximate
5-minute clotting time, but this was often partial. How-
ever, in one case we found that both the femoral artery and
the PSA coagulated after collagen injection. Although the
artery was open after 6 days, it demonstrates the existing
risk of injecting hemostatic agents in femoral PSA. It has
been described that a percutaneous thrombin injection in a
femoral PSA may be associated with an increased risk of
thrombus extension.44 For thrombin injection, various
methods are known to decrease this risk, eg, directing the
needle away from the PSA neck9 or placing a balloon in the
PSA neck.45 In case of high risk (complex) PSAs, these
methods may also prevent the risk on distal embolization
when using injectable collagen. Particularly for the complex
femoral PSA treatment, it might be attractive to combine
collagen fibrils with thrombin to not only initiate the
primary hemostasis, but also induce the secondary hemo-
stasis (clotting factor mediated). Although not tested in
this study, such an approach has been successful in giant
splenic artery pseudoaneurysm treatment.46
In view of our results, we conclude that an EtO steril-
ized, injectable 4% collagen could be prepared with defined
structural characteristics and platelet activity. In vivo, the
injectable collagen formed a dense network, which was
(partially) hemostatic active. Injectable collagen may be an
effective therapeutic alternative for current femoral PSA
treatment, but additional studies are needed to prove its
efficacy.
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